<p>Beta Bionics, Inc.（纳斯达克代码：BBNX - 获取免费报告）周一股价下跌 9.2%，此前华尔街 Zen 将该股票评级从持有下调至卖出。该公司股价最低曾达到 17.83 美元，最后交易价为 18.28 美元。在交易过程中，约有 378,461 股成交，较日均成交量 1,697,192 股下降了 78%。该股票此前收盘价为 20.14 美元。</p>
<p>其他几位研究分析师最近也对该公司发布了报告。高盛集团将 Beta Bionics 的目标价从 26.00 美元上调至 33.00 美元，并在 10 月 29 日的研究报告中给予该公司 “买入” 评级。罗伯特·W·贝尔德在 12 月 16 日的报告中设定了 Beta Bionics 的目标价为 28.00 美元。Lake Street Capital 在周五的报告中将 Beta Bionics 的目标价从 35.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。派珀·桑德勒在 10 月 29 日的报告中重申了 “增持” 评级，并将 Beta Bionics 的目标价设定为 32.00 美元（此前为 26.00 美元）。最后，Truist Financial 在 12 月 18 日的研究报告中将 Beta Bionics 的目标价从 32.00 美元上调至 37.00 美元，并给予该公司 “买入” 评级。一位分析师给予该股票 “强烈买入” 评级，七位给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Beta Bionics 的平均评级为 “适度买入”，平均目标价为 30.20 美元。</p>
<p><strong>获取我们最新的 BBNX 股票分析</strong></p>
<h2>内部活动</h2>
<p>在 Beta Bionics 的其他新闻中，董事 Maria Palasis 在 10 月 31 日的交易中出售了 1,406 股该公司的股票。该股票以平均价格 26.91 美元出售，总交易额为 37,835.46 美元。交易后，该董事在公司持有 9,841 股，价值约为 264,821.31 美元。这代表其持股减少了 12.50%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，首席财务官 Stephen Feider 在 1 月 2 日的交易中出售了 20,000 股该股票。该股票以平均价格 29.53 美元出售，总价值为 590,600.00 美元。交易完成后，首席财务官持有 42,614 股该公司的股票，价值约为 1,258,391.42 美元。这笔交易代表其持股减少了 31.94%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 35,302 股公司股票，价值为 1,036,449 美元。</p>
<h2>对 Beta Bionics 的对冲基金看法</h2>
<p>对冲基金最近买入和卖出了该公司的股票。Divisadero Street Capital Management LP 在第二季度购买了 Beta Bionics 的新股份，价值约为 13,817,000 美元。高盛集团在第一季度购买了 Beta Bionics 的新头寸，价值约为 715,000 美元。Palumbo Wealth Management LLC 在第二季度购买了 Beta Bionics 的新头寸，价值约为 431,000 美元。Sands Capital Alternatives LLC 在第二季度将其在 Beta Bionics 的持股增加了 15.0%。Sands Capital Alternatives LLC 现在持有 3,570,113 股该公司的股票，价值为 51,981,000 美元，此前在该期间又购买了 466,331 股。最后，Walleye Capital LLC 在第二季度将其在 Beta Bionics 的持股增加了 47.3%。Walleye Capital LLC 现在持有 218,189 股该公司的股票，价值为 3,177,000 美元，此前在该期间又购买了 70,084 股。</p>
<h2>Beta Bionics 价格表现</h2>
<p>该公司的 50 日移动平均线为 29.28 美元，200 日移动平均线为 22.37 美元。公司的市值为 8.0698 亿美元，市盈率为-4.19。</p>
<p>Beta Bionics（纳斯达克代码：BBNX - 获取免费报告）最后一次公布季度财报是在 10 月 28 日。该公司报告每股收益（EPS）为-0.33 美元，超出市场共识预期的-0.45 美元，超出幅度为 0.12 美元。Beta Bionics 的净利润率为-87.89%，股本回报率为-35.72%。该公司在本季度的收入为 2725 万美元，而市场共识预期为 2392 万美元。</p>
<h2>Beta Bionics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Beta Bionics 是一家总部位于马萨诸塞州波士顿的临床阶段医疗设备公司，专注于通过自动胰岛素输送解决方案来彻底改变 1 型糖尿病的管理。该公司的旗舰产品 iLet Bionic Pancreas 系统旨在通过根据连续血糖监测数据自动调整胰岛素剂量来简化血糖控制。通过将先进的算法控制与可穿戴输注泵相结合，iLet 旨在减轻糖尿病管理的日常负担，并改善患者的临床结果。</p>
<p>Beta Bionics 产品的核心是其专有的仿生胰腺软件，该软件可以在仅胰岛素和双激素模式下运行。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比 Beta Bionics 更好</li>
<li>你的银行账户不再安全</li>
<li>开火正式开始……</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护你的财富</li>
<li>在将 AI 数据中心送入轨道的竞赛中，早期参与者</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Beta Bionics 吗？</h2>
<p>在考虑 Beta Bionics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Beta Bionics 并不在名单上。</p>
<p>虽然 Beta Bionics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BBNX

<p>Beta Bionics（纳斯达克代码：BBNX）股价下跌 9.2%，因华尔街 Zen 将该股票评级从持有下调至卖出。该股最低交易价为 17.83 美元，收盘价为 18.28 美元，交易量显著下降。尽管如此，几位分析师仍设定了更高的目标价，高盛将其目标价从 26 美元上调至 33 美元。还报告了内部人士的减持，关键高管减少了持股。公司报告的季度每股收益为（0.33 美元），超出预期，营收为 2725 万美元，亦高于预期</p>

<p>Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) shares were down 9.2% on Monday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The company traded as low as $17.83 and last traded at $18.28. Approximately 378,461 shares traded hands during trading, a decline of 78% from the average daily volume of 1,697,192 shares. The stock had previously closed at $20.14.</p>
<div class="lb-trans"><p>Beta Bionics, Inc.（纳斯达克代码：BBNX - 获取免费报告）周一股价下跌 9.2%，此前华尔街 Zen 将该股票评级从持有下调至卖出。该公司股价最低曾达到 17.83 美元，最后交易价为 18.28 美元。在交易过程中，约有 378,461 股成交，较日均成交量 1,697,192 股下降了 78%。该股票此前收盘价为 20.14 美元。</p>
</div><p>Several other research analysts also recently issued reports on the company. The Goldman Sachs Group upped their price objective on Beta Bionics from $26.00 to $33.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. Robert W. Baird set a $28.00 price target on Beta Bionics in a report on Tuesday, December 16th. Lake Street Capital boosted their price objective on Beta Bionics from $35.00 to $40.00 and gave the company a &#34;buy&#34; rating in a report on Friday. Piper Sandler restated an &#34;overweight&#34; rating and issued a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Finally, Truist Financial increased their price target on Beta Bionics from $32.00 to $37.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Beta Bionics has an average rating of &#34;Moderate Buy&#34; and an average target price of $30.20.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对该公司发布了报告。高盛集团将 Beta Bionics 的目标价从 26.00 美元上调至 33.00 美元，并在 10 月 29 日的研究报告中给予该公司 “买入” 评级。罗伯特·W·贝尔德在 12 月 16 日的报告中设定了 Beta Bionics 的目标价为 28.00 美元。Lake Street Capital 在周五的报告中将 Beta Bionics 的目标价从 35.00 美元上调至 40.00 美元，并给予该公司 “买入” 评级。派珀·桑德勒在 10 月 29 日的报告中重申了 “增持” 评级，并将 Beta Bionics 的目标价设定为 32.00 美元（此前为 26.00 美元）。最后，Truist Financial 在 12 月 18 日的研究报告中将 Beta Bionics 的目标价从 32.00 美元上调至 37.00 美元，并给予该公司 “买入” 评级。一位分析师给予该股票 “强烈买入” 评级，七位给予 “买入” 评级，四位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Beta Bionics 的平均评级为 “适度买入”，平均目标价为 30.20 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BBNX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 BBNX 股票分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Beta Bionics news, Director Maria Palasis sold 1,406 shares of the company's stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $26.91, for a total transaction of $37,835.46. Following the transaction, the director owned 9,841 shares in the company, valued at approximately $264,821.31. This represents a 12.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company's stock, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 35,302 shares of company stock valued at $1,036,449.</p>
<div class="lb-trans"><p>在 Beta Bionics 的其他新闻中，董事 Maria Palasis 在 10 月 31 日的交易中出售了 1,406 股该公司的股票。该股票以平均价格 26.91 美元出售，总交易额为 37,835.46 美元。交易后，该董事在公司持有 9,841 股，价值约为 264,821.31 美元。这代表其持股减少了 12.50%。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。此外，首席财务官 Stephen Feider 在 1 月 2 日的交易中出售了 20,000 股该股票。该股票以平均价格 29.53 美元出售，总价值为 590,600.00 美元。交易完成后，首席财务官持有 42,614 股该公司的股票，价值约为 1,258,391.42 美元。这笔交易代表其持股减少了 31.94%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士已出售 35,302 股公司股票，价值为 1,036,449 美元。</p>
</div><h2>Hedge Funds Weigh In On Beta Bionics</h2>
<div class="lb-trans"><h2>对 Beta Bionics 的对冲基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Divisadero Street Capital Management LP purchased a new stake in Beta Bionics during the second quarter valued at approximately $13,817,000. Goldman Sachs Group Inc. purchased a new position in shares of Beta Bionics in the 1st quarter worth approximately $715,000. Palumbo Wealth Management LLC bought a new position in shares of Beta Bionics during the 2nd quarter valued at approximately $431,000. Sands Capital Alternatives LLC raised its holdings in Beta Bionics by 15.0% during the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company's stock valued at $51,981,000 after buying an additional 466,331 shares during the period. Finally, Walleye Capital LLC raised its holdings in Beta Bionics by 47.3% during the 2nd quarter. Walleye Capital LLC now owns 218,189 shares of the company's stock valued at $3,177,000 after buying an additional 70,084 shares during the period.</p>
<div class="lb-trans"><p>对冲基金最近买入和卖出了该公司的股票。Divisadero Street Capital Management LP 在第二季度购买了 Beta Bionics 的新股份，价值约为 13,817,000 美元。高盛集团在第一季度购买了 Beta Bionics 的新头寸，价值约为 715,000 美元。Palumbo Wealth Management LLC 在第二季度购买了 Beta Bionics 的新头寸，价值约为 431,000 美元。Sands Capital Alternatives LLC 在第二季度将其在 Beta Bionics 的持股增加了 15.0%。Sands Capital Alternatives LLC 现在持有 3,570,113 股该公司的股票，价值为 51,981,000 美元，此前在该期间又购买了 466,331 股。最后，Walleye Capital LLC 在第二季度将其在 Beta Bionics 的持股增加了 47.3%。Walleye Capital LLC 现在持有 218,189 股该公司的股票，价值为 3,177,000 美元，此前在该期间又购买了 70,084 股。</p>
</div><h2>Beta Bionics Price Performance</h2>
<div class="lb-trans"><h2>Beta Bionics 价格表现</h2>
</div><p>The business has a 50-day moving average of $29.28 and a 200-day moving average of $22.37. The company has a market capitalization of $806.98 million and a P/E ratio of -4.19.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 29.28 美元，200 日移动平均线为 22.37 美元。公司的市值为 8.0698 亿美元，市盈率为-4.19。</p>
</div><p>Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The business had revenue of $27.25 million during the quarter, compared to the consensus estimate of $23.92 million.</p>
<div class="lb-trans"><p>Beta Bionics（纳斯达克代码：BBNX - 获取免费报告）最后一次公布季度财报是在 10 月 28 日。该公司报告每股收益（EPS）为-0.33 美元，超出市场共识预期的-0.45 美元，超出幅度为 0.12 美元。Beta Bionics 的净利润率为-87.89%，股本回报率为-35.72%。该公司在本季度的收入为 2725 万美元，而市场共识预期为 2392 万美元。</p>
</div><h2>Beta Bionics Company Profile</h2>
<div class="lb-trans"><h2>Beta Bionics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.</p>
<div class="lb-trans"><p>Beta Bionics 是一家总部位于马萨诸塞州波士顿的临床阶段医疗设备公司，专注于通过自动胰岛素输送解决方案来彻底改变 1 型糖尿病的管理。该公司的旗舰产品 iLet Bionic Pancreas 系统旨在通过根据连续血糖监测数据自动调整胰岛素剂量来简化血糖控制。通过将先进的算法控制与可穿戴输注泵相结合，iLet 旨在减轻糖尿病管理的日常负担，并改善患者的临床结果。</p>
</div><p>At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.</p>
<div class="lb-trans"><p>Beta Bionics 产品的核心是其专有的仿生胰腺软件，该软件可以在仅胰岛素和双激素模式下运行。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Beta Bionics</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Shots officially fired…</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Early-Entry Player in the Race to Put AI Data Centers in Orbit</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Beta Bionics 更好</li>
<li>你的银行账户不再安全</li>
<li>开火正式开始……</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护你的财富</li>
<li>在将 AI 数据中心送入轨道的竞赛中，早期参与者</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Beta Bionics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Beta Bionics 吗？</h2>
</div><p>Before you consider Beta Bionics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Beta Bionics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Beta Bionics 并不在名单上。</p>
</div><p>While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Beta Bionics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Beta Bionics（NASDAQ:BBNX）股价下跌 9.2%，因分析师下调其评级